Drugs / GB-0895
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07116889 | Dec 2023 → May 2027 expected | asthma, chronic obstructive pulmonary disease | Generate Biomedicines | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07359846 | Jan 2026 → Jan 2029 expected | asthma | Generate Biomedicines | Recruiting | No outcome recorded |
| Phase 3 | NCT07276724 | Dec 2025 → Dec 2028 expected | asthma | Generate Biomedicines | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-25 | Generate Biomedicines | Results Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress generatebiomedicines.com ↗
GB-0895 was well tolerated across a wide dose range of 10 mg to 1200 mg and demonstrated dose-proportional pharmacokinetics with a prolonged half-life of ~89 days. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-01 | Generate Biomedicines | Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI generatebiomedicines.com ↗ |
| 2025-09-25 | Generate Biomedicines | Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress generatebiomedicines.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB-0895 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07116889 ↗ |
| Route | Subcutaneous | “Single subcutaneous dose of GB-0895” NCT07116889 ↗ |